ProPhase Labs Q2 revenue $13.2M, down 55% YoY; adjusted EBITDA loss $2.2M

ProPhase Labs, Inc.

2023-Q2 EPS reported -$0.17 revenue$32,520,000

Revenue $13.2M vs $29.1M YoY; diagnostic services fell $18.3M as COVID testing slowed.
Gross margin fell to 48.8% from 64.3%; net working capital $40.2M.
Nebula Genomics whole genome sequencing facility could generate ~$40M annual revenue at capacity.
Pharmaloz Manufacturing revenue up >50% YoY; additional lozenge line planned for early 2024.
Equivir trial enrollment commenced in India; BE-SMART test progressed with over 200 specimens.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProPhase Labs, Inc. reported the three months ended June 30, 2023 results: net income adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million.

Period: the three months ended June 30, 2023
Net income: adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million
Result: reported results

Exact text from the filing

On August 10, 2023, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027445

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.